Adecatumumab

• CAT Number: I042429
• CAS Number: 503605-66-1
• Purity: ≥95%

Adecatumumab (Cat No.: I042429) is a fully human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM), a protein overexpressed in various epithelial cancers such as breast, colon, and prostate cancer. By binding to EpCAM, adecatumumab disrupts tumor cell adhesion, inhibits proliferation, and may trigger immune-mediated cytotoxicity. It has been evaluated in clinical trials for its potential to reduce tumor progression and metastasis. While development has been limited, adecatumumab remains a valuable tool in cancer immunotherapy research and EpCAM-targeted therapeutic strategies.

Reference

[1]. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
[Content Brief]

[2]. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68.
[Content Brief]